While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...

Sanofi SAN1.73%increase; green up pointing triangle forecast stronger earnings growth this year and said it planned to launch a $5.2 billion share buyback. The French pharmaceutical company said ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

Sanofi's consumer healthcare unit Opella could finally be able to bring an OTC PDE-5 inhibitor for erectile dysfunction to the US market. Join the conversation, on Tuesday 28th January @ 10 am ET ...

After hours: January 31 at 5:57:14 PM EST Loading Chart for SNY ...

A line extension of one of Sanofi Indias flagship brand Combiflam, the launch of this new product marks the companys foray into the OTC headache segment in India.On 11 November 2014, Sanofi India ...

At close: January 28 at 5:38:58 PM GMT+1 ...

If you have trouble hearing in noisy environments and often find yourself asking people to repeat themselves but your hearing loss isn't severe, OTC hearing aids can be helpful. Hearing aids ...

After hours: 7:59:17 pm GMT-5 ...